Atomoxetine
As of the edition of 20 October 2026, Atomoxetine is a small molecule: marketed, first approved in 2002 (US); acts on SLC6A2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Strattera
- First approved
- 26 November 2002 (US)
- Approvals on record
- 11 in 2 regions
- Holder of the most recent approval
- Map77; 2 holders in all
- Registered trials
- 141, 8 stopped early
- Disease areas
- Mental health; Nervous system; Chemically induced; Lungs and airways; Heart and blood vessels; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SLC6A2 | Sodium-dependent noradrenaline transporter | P23975 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 22 | 17 | 1 | 0 |
| Phase 1 | 10 | 7 | 1 | 2 |
| Phase 2 | 30 | 24 | 2 | 2 |
| Phase 3 | 30 | 27 | 2 | 1 |
| Phase 4 | 49 | 40 | 3 | 3 |
| All trials | 141 |